This double-blind, placebo-controlled randomized trial will assess whether 14 days of oral carnitine supplementation modifies mitochondrial fatty acid processing in healthy young adults.
This project will use stable isotope techniques and magnetic resonance spectroscopy (MRS) to take a first step toward clarifying how the benefit of oral carnitine supplementation depends on basal mitochondrial fatty acid processing (MFAP) and MFAP modification, with a specific focus on the liver. Approximately 24 healthy young individuals will be enrolled, with 20 expected to complete. Before and after 14 days of oral carnitine supplementation or placebo, MFAP will be measured using measures of acetyl-carnitine concentration (from long-TE proton MRS) and de novo lipogenesis (DNL, from analysis of blood metabolites following 13C-labeled acetate infusion and high-fructose drink challenge). The MFAP measures will be collected before and after loading participants with a high-fructose drink. Fructose is solely metabolized by the liver.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
24
500 mg tablets of L-Carnitine taken 3 times daily before meals.
500 mg tablets of L-Carnitine taken 3 times daily before meals.
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Liver mitochondrial fatty acid processing
Change from baseline in liver mitochondrial fatty acid processing during high-fructose drink challenge
Time frame: Day 18
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.